Skip to main content
. 2011 Jun 23;7:391–398. doi: 10.2147/NDT.S20589

Table 4.

Frequency of adverse events during the study period (efficacy population)

Adverse events reported by ≥5% of patients, n (%) n = 53
Insomnia 12 (22.6)
Increased prolactin 9 (17.0)
Weight gain 7 (13.2)
Anxiety 3 (5.7)
Epigastralgia 3 (5.7)
Reduced appetite 3 (5.7)
Adverse events related to the study drug, n (%) n = 53
Increased prolactin 9 (17.0)
Weight gain 5 (9.4)